HIV-1 entry inhibitor entrances

Trends in Pharmacological Sciences

Volumn 25, Issue 3, 2004, Pages 117-120

  Kuhmann, Shawn E ^a   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 070; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; PRO 140; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; TNX 355; UK 427 857; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; CELL ADHESION; CELL FUSION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS ISOLATION; VIRUS REPLICATION;

EID: 1342264247     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.01.005     Document Type: Short Survey

References (23)

1. Lazzarin A., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2003;2186-2195.
2. Lalezari J.P., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New Engl. J. Med. 348:2003;2175-2185.
3. Kilby J.M., Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. New Engl. J. Med. 348:2003;2228-2238.
4. Moore J.P., Doms R.W. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U. S. A. 100:2003;10598-10602.
5. Lin P.F., et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U. S. A. 100:2003;11013-11018.
6. Guo Q., et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77:2003;10528-10536.
7. Wang T., et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b] pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46:2003;4236-4239.
8. Kwong P.D., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
9. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1998;1884-1888.
10. Tsamis F., et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77:2003;5201-5208.
11. Hammer S.M. HIV drug resistance: implications for management. Top. HIV Med. 10:2002;10-15.
12. Wei X., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:2002;1896-1905.
13. de Vreese K., et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70:1996;689-696.
14. Kanbara K., et al. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res. Hum. Retroviruses. 17:2001;615-622.
15. Trkola A., et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U. S. A. 99:2002;395-400.
16. Kuhmann, S.E. et al. (2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small molecule CCR5 inhibitor. J. Virol. (in press).
17. Rusconi S., et al. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. J. Virol. 74:2000;9328-9332.
18. Nagashima K.A., et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183:2001;1121-1125.
19. Tremblay C.L., et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46:2002;1336-1339.
20. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 1:2002;977-985.
21. Shattock R.A., Moore J.P. Inhibiting HIV-1 sexual transmission. Nat. Rev. Microbiol. 1:2003;25-34.
22. Veazey R.S., et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:2003;343-346.
23. Moore J.P., Shattock R.J. Preventing HIV-1 sexual transmission-not sexy enough science, or no benefit to the bottom line? J. Antimicrob. Chemother. 52:2003;890-892.